AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Day One shares surge 12.96% after-hours on positive 3-year FIREFLY-1 trial data and Mersana acquisition.
ByAinvest
Thursday, Dec 18, 2025 5:33 pm ET1min read
Day One Biopharmaceuticals (DAWN) surged 12.96% in after-hours trading following the release of positive three-year follow-up results from its pivotal Phase 2 FIREFLY-1 trial of OJEMDA (tovorafenib), demonstrating sustained efficacy and safety in treating pediatric low-grade glioma. The data, announced ahead of the 2025 Society for Neuro-Oncology Annual Meeting, reinforced the drug’s commercial potential. Additionally, the company’s acquisition of Mersana Therapeutics, valued up to $285 million, expanded its pipeline of antibody-drug conjugate technologies, signaling strategic growth and operational synergy. These developments, emphasizing therapeutic innovation and pipeline expansion, directly aligned with the stock’s upward trajectory, overshadowing unrelated news about competitors or non-healthcare events.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet